ImmunityBio, Inc. (NASDAQ:IBRX) filed its annual report (Form 10-K) with the Securities and Exchange Commission on February 23, 2026.
The Healthcare company reported annual revenue of and net income of for fiscal year 0.
ImmunityBio, Inc.'s stock currently trades at $9.83 with a market capitalization of $2.2B.